Megadose Methylprednisolone for Kasabach-Merritt Syndrome

Abstract

Dresse et al¹ recently presented their success in the treatment of Kasabach-Merritt syndrome by using prednisone and epsilon amino caproic acid (EACA). Among several approaches in the treatment of this syndrome the authors failed to mention megadose methylprednisolone^2,3 (MDMP; daily 30 mg/kg with gradual tapering). Although previously it was used intravenously, recently it is found equally effective when given orally, which is another advantage of this treatment.